DFS |
| Prognostic factors |
Univariate analysis |
Multivariate analysis |
| HR |
95% CI |
P |
| Age |
0.297 |
0.68 |
0.325-1.42 |
0.3 |
| Hematogons≥ 0.01% |
<0.001 |
2.3 |
3.12-33.3 |
< 0.0001 |
| Leucoytosis |
0.166 |
0.58 |
0.29-1.16 |
0.125 |
| No. of chemotherapy cycles to achieve CR |
<0.0001 |
0.318 |
0.07-1.4 |
< 0.0001 |
| Cytogenetics |
|
|
|
|
| Favorable |
<0.0001 |
0.799 |
0.245-2.610 |
0.710 |
| Intermediate |
1.225 |
0.400-3.752 |
0.722 |
| Poor |
6.024 |
1.774-20.4 |
0.004 |
OS |
| Prognostic factors |
Univariate analysis |
Multivariate analysis |
| HR |
95% CI |
P |
| Age |
0.152 |
0.513 |
0.2-1.3 |
0.162 |
| Hematogons ≥ 0.01% |
0.013 |
1.6 |
1.2-22.9 |
0.007 |
| Leucoytosis |
0.136 |
2.134 |
0.766-5.944 |
0.147 |
| No. of chemotherapy cycles to achieve CR |
0.002 |
0.218 |
0.017- 2.790 |
0.241
. |
| Cytogenetics |
|
|
|
|
| Favorable |
<0.0001 |
0.605 |
0.68-5.375 |
0.652 |
| Intermediate |
1.468 |
0.243-8.868 |
0.676 |
| Poor |
3.741 |
0.653-21.422 |
0.138 |
|
